Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.12% |
| 2 | Technology | 12.96% |
| 3 | Healthcare | 12.08% |
| 4 | Industrials | 11.23% |
| 5 | Consumer Staples | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Kennametal
KMT
$2.32B
| $27.1M | 0.04% |
868,000
-46,400
| -5% | -$1.46M |
|
602
Rambus
RMBS
$10.8B
| $27.1M | 0.04% |
1,966,200
+253,300
| +15% | +$3.28M |
|
|
XXIA
603
DELISTED
Ixia
XXIA
| $27M | 0.04% |
1,676,220
+156,000
| +10% | +$2.16M |
|
604
Orthofix Medical
OFIX
$415M
| $27M | 0.04% |
745,579
+221,379
| +42% | +$8.4M |
|
605
MarketAxess Holdings
MKTX
$5.72B
| $27M | 0.04% |
+183,510
| New | +$29.2M |
|
606
Energy Transfer Partners
ET
$71.5B
| $26.9M | 0.04% |
1,395,152
+1,231,800
| +754% | +$20.6M |
|
|
HSII
607
DELISTED
Heidrick & Struggles
HSII
| $26.9M | 0.04% |
1,111,986
+21,884
| +2% | +$461K |
|
|
AJRD
608
DELISTED
Aerojet Rocketdyne Holdings
AJRD
| $26.8M | 0.04% |
1,494,795
+133,495
| +10% | +$2.46M |
|
609
Digital Realty Trust
DLR
$73.1B
| $26.8M | 0.04% |
272,800
+17,200
| +7% | +$1.6M |
|
610
Sony
SONY
$138B
| $26.8M | 0.04% |
4,778,500
-2,741,500
| -36% | -$16.7M |
|
|
TVTY
611
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $26.7M | 0.04% |
1,175,189
-450,268
| -28% | -$10.6M |
|
|
KYO
612
DELISTED
Kyocera Adr
KYO
| $26.7M | 0.04% |
536,900
-900
| -0.2% | -$44K |
|
|
CATM
613
DELISTED
Cardtronics plc Class A Ordinary Shares (UK)
CATM
| $26.7M | 0.04% |
488,500
+142,300
| +41% | +$7.24M |
|
|
EGOV
614
DELISTED
NIC Inc
EGOV
| $26.6M | 0.04% |
1,114,300
-30,960
| -3% | -$741K |
|
615
Marriott International
MAR
$91.9B
| $26.5M | 0.04% |
320,116
-524,000
| -62% | -$39.4M |
|
616
Primerica
PRI
$9.62B
| $26.4M | 0.04% |
381,999
+218,599
| +134% | +$13.9M |
|
|
CCMP
617
DELISTED
CMC Materials, Inc. Common Stock
CCMP
| $26.4M | 0.04% |
417,900
-13,600
| -3% | -$786K |
|
|
IBA
618
DELISTED
Industrias Bachoco SAB De C.V.
IBA
| $26.3M | 0.04% |
536,300
+4,900
| +0.9% | +$243K |
|
|
PHH
619
DELISTED
PHH Corporation
PHH
| $26.3M | 0.04% |
1,731,500
+433,600
| +33% | +$6.41M |
|
620
Waters Corp
WAT
$40.6B
| $26.2M | 0.04% |
195,300
+175,100
| +867% | +$25M |
|
621
Adtran
ADTN
$658M
| $26.2M | 0.04% |
1,173,628
-76,700
| -6% | -$1.55M |
|
622
ON Semiconductor
ON
$31.8B
| $26.1M | 0.04% |
2,044,560
+754,164
| +58% | +$9M |
|
|
DISH
623
DELISTED
DISH Network Corp.
DISH
| $26M | 0.04% |
448,579
-547,400
| -55% | -$31.3M |
|
|
BRSS
624
DELISTED
Global Brass & Copper Hldgs, Inc
BRSS
| $26M | 0.04% |
756,900
+61,700
| +9% | +$1.86M |
|
|
PBPB
625
DELISTED
Potbelly
PBPB
| $25.8M | 0.04% |
2,002,900
+117,600
| +6% | +$1.57M |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.